Charles River Laboratories Announces Divestitures and Updates 2026 Guidance

Details

announced on February 25, 2026, that it has signed definitive agreements to divest its CDMO and Cell Solutions businesses to GI Partners and certain European Discovery Services assets to IQVIA Holdings Inc. These divestitures are expected to close during the second quarter of 2026 and will result in a reduction of reported revenue by slightly more than $200 million and a more than 50-basis-point reduction to organic revenue growth guidance for 2026. The Company has also updated its 2026 financial guidance, projecting non-GAAP earnings per share of $10.80 - $11.30, reflecting at least 100 basis points of incremental non-GAAP operating margin improvement.

Items reported

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. provides essential services to the pharmaceutical, biotechnology, and life sciences industries. The company specializes in preclinical and clinical lab services, offering clients a comprehensive suite of drug discovery and development services that expedite the process of getting new drugs and therapies to the market. Notably, Charles River's facilities offer expertise in the fields of oncology, immunology, and neuroscience, making it a critical partner for companies working in these therapeutic areas. The firm operates globally, enhancing its customers' ability to operate internationally through its wide network of laboratories and testing facilities. By enabling more efficient drug development cycles and reducing the time to market for new therapies, Charles River Laboratories plays a crucial role in the advancement of medical science and patient care worldwide. The company's commitment to high standards of animal welfare and ethical practices further underscores its reputation as a leader in quality and reliability within the research community.